Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MONA AMIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1740476217
CMS profile
125054
Location
GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$34,509.84

233 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MONA AMIN

NPI 1740476217 · CMS profile ID 125054

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740476217?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MONA AMIN, NPI 1740476217, CMS profile ID 125054. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740476217?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MONA AMIN, NPI 1740476217, CMS profile ID 125054. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740476217?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MONA AMIN, NPI 1740476217, CMS profile ID 125054, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 233 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740476217?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

233 matching records · $34,509.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 233 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 233.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $330.4009/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064379 CMS
Lilly USA, LLC $900.0009/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818592429 CMS
AbbVie Inc. $17.8309/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879037 CMS
Amgen Inc. $7.5409/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638767 CMS
AbbVie Inc. $20.0609/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879033 CMS
Amgen Inc. $3.8409/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638747 CMS
Aurinia Pharma U.S., Inc. $3.5109/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841389937 CMS
AbbVie Inc. $25.6609/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879029 CMS
Horizon Therapeutics plc $60.6109/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064369 CMS
Horizon Therapeutics plc $92.5409/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064353 CMS
Horizon Therapeutics plc $4,080.0009/16/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064357 CMS
Horizon Therapeutics plc $106.2709/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064361 CMS
Horizon Therapeutics plc $382.3909/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064365 CMS
Aurinia Pharma U.S., Inc. $5.6509/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841389933 CMS
Lilly USA, LLC $33.6809/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818607487 CMS
Amgen Inc. $15.3309/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638823 CMS
GlaxoSmithKline, LLC. $17.4909/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801861397 CMS
Horizon Therapeutics plc $8.2109/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064349 CMS
AbbVie Inc. $17.2809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879025 CMS
Amgen Inc. $5.5709/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638763 CMS
Amgen Inc. $7.4009/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638877 CMS
Aurinia Pharma U.S., Inc. $206.9909/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841389929 CMS
PFIZER INC. $18.0009/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832926345 CMS
PFIZER INC. $25.8009/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832935179 CMS
Amgen Inc. $16.9409/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638873 CMS
Aurinia Pharma U.S., Inc. $17.4509/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841389925 CMS
Horizon Therapeutics plc $6.4609/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064343 CMS
PFIZER INC. $26.1909/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832901533 CMS
PFIZER INC. $3.9309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832945301 CMS
Janssen Biotech, Inc. $14.6808/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788632633 CMS
Janssen Biotech, Inc. $16.2108/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788632635 CMS
Genentech USA, Inc. $16.9908/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835954827 CMS
AbbVie Inc. $6.5208/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879021 CMS
Amgen Inc. $14.7208/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638819 CMS
Amgen Inc. $23.5108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638869 CMS
Horizon Therapeutics plc $117.3708/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064335 CMS
Horizon Therapeutics plc $2,448.0008/12/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064339 CMS
Amgen Inc. $7.0308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638743 CMS
PFIZER INC. $12.6008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832924803 CMS
UCB, Inc. $21.0308/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807320173 CMS
UCB, Inc. $1.1008/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807401835 CMS
Amgen Inc. $14.3208/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825638815 CMS
PFIZER INC. $16.1908/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832910597 CMS
AbbVie Inc. $7.1608/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879017 CMS
Horizon Therapeutics plc $19.5908/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064331 CMS
UCB, Inc. $30.3408/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807384725 CMS
Novartis Pharmaceuticals Corporation $22.6007/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812587053 CMS
AbbVie Inc. $24.7207/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879013 CMS
AbbVie Inc. $20.3407/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793879009 CMS
Horizon Therapeutics plc $7.0707/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797064317 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $113,991.51 385
PY2020 $35,036.97 211
PY2021 $34,509.84 233
PY2022 $44,854.05 215
PY2023 $114,010.70 274
PY2024 $64,376.20 242
PY2025 $38,990.08 211

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $291,002.96 48
PY2024 Recipient $5,704.58 2
PY2024 Principal investigator $749,553.08 79
PY2023 Recipient $1,221.92 3
PY2023 Principal investigator $1,579,201.72 123
PY2022 Principal investigator $528,872.46 199
PY2021 Recipient $1,585.16 2
PY2021 Principal investigator $1,286,169.96 196
PY2020 Recipient $349.81 1
PY2020 Principal investigator $438,736.84 119
PY2019 Recipient $89,679.00 1
PY2019 Principal investigator $151,877.63 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,045.25 12/25/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228790155
Principal investigator 1 PFIZER INC. $12,125.70 11/26/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228818544
Principal investigator 1 PFIZER INC. $769.55 10/28/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228818502
Principal investigator 1 PFIZER INC. $395.55 08/22/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228828584
Principal investigator 1 PFIZER INC. $2,019.72 07/16/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228831106
Principal investigator 1 PFIZER INC. $10,937.94 07/11/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228830990
Principal investigator 1 PFIZER INC. $14,252.00 07/11/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228831101
Principal investigator 1 Janssen Research & Development, LLC $400.00 07/10/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396240
Principal investigator 1 PFIZER INC. $1,633.65 06/26/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228829475
Principal investigator 1 Eli Lilly and Company $5,600.00 06/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1187873797
Principal investigator 1 Eli Lilly and Company $29,084.00 06/16/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876055
Principal investigator 1 Janssen Research & Development, LLC $4,080.00 06/02/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396083
Principal investigator 1 PFIZER INC. $2,257.20 05/29/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228811652
Principal investigator 1 PFIZER INC. $6,594.48 05/14/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228832565
Principal investigator 1 Eli Lilly and Company $38.25 05/08/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877165
Principal investigator 1 CSL Behring $650.00 05/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667829
Principal investigator 1 CSL Behring $1,500.00 05/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667831
Principal investigator 1 CSL Behring $1,500.00 05/02/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667837
Principal investigator 1 CSL Behring $385.00 04/25/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667827
Principal investigator 1 PFIZER INC. $2,817.99 04/24/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228833107
Principal investigator 1 Eli Lilly and Company $1,854.70 04/23/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875675
Principal investigator 1 Janssen Research & Development, LLC $258.00 03/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175395947
Principal investigator 1 PFIZER INC. $3,065.04 03/26/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228831328
Principal investigator 1 Eli Lilly and Company $710.21 03/25/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873533
Principal investigator 1 Janssen Research & Development, LLC $206.00 03/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396178
Principal investigator 1 Janssen Research & Development, LLC $6,750.00 03/17/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175395966
Principal investigator 1 Janssen Research & Development, LLC $487.00 03/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175395865
Principal investigator 1 Janssen Research & Development, LLC $347.00 03/14/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175395884
Principal investigator 1 CSL Behring $1,000.00 03/05/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667825
Principal investigator 1 CSL Behring $1,000.00 03/05/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667835
Principal investigator 1 PFIZER INC. $4,111.14 02/26/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228826176
Principal investigator 1 CSL Behring $100.00 02/24/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667819
Principal investigator 1 CSL Behring $300.00 02/24/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667821
Principal investigator 1 CSL Behring $1,340.00 02/24/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667823
Principal investigator 1 CSL Behring $300.00 02/24/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667833
Principal investigator 1 Janssen Research & Development, LLC $2,483.00 02/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175395870
Principal investigator 1 Janssen Research & Development, LLC $258.00 02/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175396143
Principal investigator 1 CSL Behring $67.50 02/19/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667813
Principal investigator 1 CSL Behring $156.00 02/19/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667815
Principal investigator 1 CSL Behring $202.50 02/19/2025 Non-covered Recipient Entity
Arizona Arthritis and Rheaumatology Research
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252667817
Principal investigator 1 Janssen Research & Development, LLC $126.00 02/13/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RE SEARCH PLLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175396019
Principal investigator 1 UCB SA $30,673.00 02/05/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246656291
Principal investigator 1 Eli Lilly and Company $48,189.00 02/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874363
Principal investigator 1 Eli Lilly and Company $14,208.00 01/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876445
Principal investigator 1 PFIZER INC. $4,012.47 01/24/2025 Non-covered Recipient Entity
Arizona Arthritis Rheumatology Research PLLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228831215
Principal investigator 1 Eli Lilly and Company $31,720.57 01/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874639
Principal investigator 1 Eli Lilly and Company $36,959.00 01/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187877157
Principal investigator 1 UCB SA $1,032.55 01/15/2025 Non-covered Recipient Entity
Arizona Arthritis And Rheumatology Associates, Pc
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657458